Lactate dehydrogenase (LDH) levels to predict benefit from the continuation of bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Subgroup analysis of the randomized BEBYP study.

Federica Marmorino,Chiara Cremolini,Fotios Loupakis,C. Barbara,F. Dargenio,Emanuela Miraglio,Gianluca Masi,Lisa Salvatore,Lorenzo Marcucci,Lorenzo Antonuzzo,Silvana Chiara,C. Banzi,Marta Schirripa,D. Amoroso,Andrea Bonetti,Angelo Martignetti,Myriam Paris,Luca Boni,Daniela Tomčíková,Alfredo Falcone

Lactate dehydrogenase (LDH) levels to predict benefit from the continuation of bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Subgroup analysis of the randomized BEBYP study.

2016

e15127Background: Different antiangiogenic agents are available as 2nd line options for mCRC patients (pts). Up today, no clinical or molecular predictors of benefit have been identified. In precli...

Keywords:

Bevacizumab
Lactate dehydrogenase
Subgroup analysis
Physical therapy
Continuation
Colorectal cancer
Cancer research
Medicine
Oncology
Antiangiogenic agents
Internal medicine
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations